PACB: Pacific Biosciences of California Price-to-Revenue Coefficient

Symbol and logo of brand Pacific Biosciences of California, Inc. (PACB)

Pacific Biosciences dominates high-accuracy HiFi sequencing, implementing AI algorithms and innovative Revio and Onso systems to expand its presence in the genomics market. Fluctuations in the P/S multiple reflect the business valuation dynamics, with the indicator reaching 3.80. The company's stability is supported by the diversification of solutions for microbiology, the agricultural sector, and clinical genetics, which significantly reduces operational risks.

PACB PacBio Price-to-Revenue Ratio (07/04/2022 - 11/13/2026)

Analytical breakdowns for Pacific Biosciences of California (PACB)

- current price and projected stock value:
Price Chart pacb.com|PACB - Analyst Consensus Forecast
- market capitalization information:
Market Capitalization Pacific Biosciences of California|PACB - Total Company Value
- company book value details:
Net Asset Value per Share PacBio|PACB - Company Book Value|Market Capitalization to Book Value pacb.com|PACB - Company Total Assets
- issuer credit burden and liquidity indicators:
Total Debt to Equity Ratio Pacific Biosciences|PACB - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient PacBio Corp|PACB - Company Aggregate Debts|Debts to Book Value Pacific Biosciences of California|PACB - Company Long-Term Debt|Company Short-Term Indebtedness PacBio|Quick Liquidity Indicator pacb.com
- earnings and multiples data:
PACB - Net Profit|Expected Net Profit Pacific Biosciences|PACB - Price to Earnings Ratio|Market Cap to Projected Earnings Pacific Biosciences of California, Inc.|PACB - Price/Earnings to Growth Ratio|Company Value to Operating Income Before Depreciation Ratio Pacific Biosciences of California|PACB - Operating profit EBITDA|Net earnings per share (EPS TTM) PacBio|PACB - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months pacb.com|PACB - Earnings growth in current year|Net earnings per share growth forecast for next year Pacific Biosciences
- total revenue and sales volume data:
PACB - Revenue and Sales Volume|Company Revenue Forecast pacb.com|PACB - Price-to-Revenue Ratio|Market Cap to Projected Revenue Pacific Biosciences of California
General company analysis:PACB - pacb.com
Original product of Pacific Biosciences

The P/S ratio reflects the market value of the business per unit of generated revenue, allowing for an assessment of the premium paid for future revenue growth. Analyzing the current price-to-sales value is critical for Pacific Biosciences (PACB), as US export restrictions and chip supply disruptions directly impact the deployment rates of sequencing systems, determining the fundamental fairness of the company's market valuation.

Competitors of Pacific Biosciences

Price-to-Revenue Ratio TEM (Tempus AI)|P/S Multiple QGEN (Qiagen)|Price-to-Revenue Coefficient Ionis Pharmaceuticals, Inc. (IONS)|RGEN - Price-to-Revenue Ratio|Price to Sales Avidity Corp|CRISPR Therapeutics AG (CRSP) - Price-to-Revenue Ratio|WGS - Price-to-Revenue Coefficient|RARE (Ultragenyx) - P/S Multiple|Market Cap to Revenue Beam Therapeutics Inc (BEAM)|P/S Multiple SRPT|Price-to-Revenue Coefficient Twist Bioscience Corp|P/S Multiple TXG (10x Genomics, Inc.)|intelliatx.com (NTLA) - Price to Sales|STOK - Price-to-Revenue Ratio|BLFS (BioLife Solutions Inc) - Market Cap to Revenue Ratio|WVE: P/S Multiple|Market Cap to Revenue Maze Therapeutics Corp|SION (Sionna Therapeutics Inc) - P/S Multiple|Price to Sales primemedicine.com PRME|Price-to-Revenue Ratio Taysha Gene Therapies, Inc. (TSHA)|Price-to-Revenue Coefficient uniQure NV|Price-to-Revenue Ratio MeiraGTx PLC MGTX|RGNX (REGENXBIO Corp) - Price-to-Sales Ratio|Solid Biosciences Inc. - P/S Multiple|OCGN - P/S Multiple|BNTC: P/S Multiple|Market Cap to Revenue Design Therapeutics Inc|RCKT (Rocket Pharmaceuticals Inc) - P/S Multiple|Price-to-Revenue Ratio FDMT|P/S Multiple LXEO|korrobio.com - Market Cap to Revenue Ratio|Price-to-Revenue Ratio Editas Medicine EDIT|SLN: Market Cap to Revenue Ratio|ProQR Therapeutics NV - P/S Multiple|CDXS - P/S Multiple|Sangamo Therapeutics (SGMO) - Price-to-Revenue Ratio|Price-to-Sales Ratio NAUT (Nautilus Bio)|MGX (Metagenomi) - P/S Multiple|P/S Multiple precisionbiosciences.com|P/S Multiple GBIO|Market Cap to Revenue Boundless Bio Inc BOLD|P/S Multiple XCUR (Exicure)|Price-to-Revenue Coefficient Imunon Inc (IMNN)|RXi Pharmaceuticals - P/S Multiple|Price-to-Sales Ratio MBIO|RNAZ: P/S Multiple|BNGO - Price-to-Revenue Coefficient|APDN (Applied DNA Sciences) - P/S Multiple|Market Cap to Revenue bluebirdbio.com (BLUE)|Market Cap to Revenue IPA (ImmunoPrecise Antibodies)|OMGA (Omega Therapeutics Inc) - Market Capitalization-to-Revenue Ratio|P/S Multiple OMIC (Singular Genomics Systems Inc)|Regulus - Price-to-Revenue Ratio|Syros Pharmaceuticals - P/S Multiple|Price-to-Revenue Coefficient telesisbio.com TBIO|TRACON Pharmaceuticals, Inc. (TCON) - Price-to-Revenue Ratio|Price to Sales Unity Biotechnology Inc. (UBX)